SWX:LONN Earnings and Revenue History April 11th 2025 How Do Unusual Items Influence Profit? To properly understand Lonza Group's profit results, we need to consider the CHF284m e ...

Lonza Group Ag (LZAGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...

Lonza is poised for growth amid margin recovery, onshoring opportunities, and strong profit projections. Read more on LZAGY ...

In a report released today, Patrick Rafaisz from UBS maintained a Buy rating on Lonza Group Ltd (LONN – Research Report), with a price target ...

Lonza Group AG / Key word (s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel, ...

Revenue: CHF6.57b (down 2.1% from FY 2023). Net income: CHF636.0m (down 2.8% from FY 2023). Profit margin: 9.7% (in line with FY 2023). EPS: CHF8.94. Trump has pledged to "unleash" American oil ...